Efficacy of raloxifene for treatment of menopause: a systematic review (Q34631937)

3 August 2017

1 reference

title

Efficacy of raloxifene for treatment of menopause: a systematic review (English)

1 reference

3 August 2017

1 reference

Mark Boyack

1

1 reference

3 August 2017

Sandra Lookinland

series ordinal

2

1 reference

3 August 2017

Susan Chasson

series ordinal

3

1 reference

3 August 2017

publication date

1 April 2002

1 reference

Journal of the American Academy of Nurse Practitioners

3 August 2017

published in

1 reference

3 August 2017

volume

14

1 reference

3 August 2017

issue

4

1 reference

3 August 2017

page(s)

150-165

1 reference

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2002.TB00107.X

A method for assessing the quality of a randomized control trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2002.TB00107.X

Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2002.TB00107.X

Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2002.TB00107.X

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2002.TB00107.X

Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2002.TB00107.X

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2002.TB00107.X

Claims of equivalence in medical research: are they supported by the evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2002.TB00107.X

A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2002.TB00107.X

Long-term effects of continuous combined HRT on bone turnover and lipid metabolism in postmenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2002.TB00107.X

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2002.TB00107.X

Clinical effects of raloxifene hydrochloride in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2002.TB00107.X

Treatment of postmenopausal osteoporosis with transdermal estrogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2002.TB00107.X

Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2002.TB00107.X

Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2002.TB00107.X

Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2002.TB00107.X

Cardiovascular disease risk and hormone replacement therapy (HRT): a review based on randomised, controlled studies in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2002.TB00107.X

CONSORT: An Evolving Tool to Help Improve the Quality of Reports of Randomized Controlled Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2002.TB00107.X

Lifetime risk of developing coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2002.TB00107.X

Therapy for Fracture Prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2002.TB00107.X

10.1111/J.1745-7599.2002.TB00107.X

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference